The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 20, 2016
Filed:
Mar. 13, 2014
Applicant:
Thomas Cooper Woods, New Orleans, LA (US);
Inventor:
Thomas Cooper Woods, New Orleans, LA (US);
Assignee:
Other;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 31/277 (2006.01); A61K 31/00 (2006.01); C12N 15/113 (2010.01); A61K 45/06 (2006.01); A61K 31/436 (2006.01); C12N 15/11 (2006.01); A61K 31/275 (2006.01);
U.S. Cl.
CPC ...
A61K 31/277 (2013.01); A61K 31/00 (2013.01); A61K 31/275 (2013.01); A61K 31/436 (2013.01); A61K 45/06 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); C12N 2310/113 (2013.01); C12N 2320/30 (2013.01);
Abstract
The present invention relates to methodology for preventing increased cardiovascular disease in subjects with diabetes mellitus. The methods include the use of compounds to inhibit activation of the extracellular response kinase pathway, activate 5' adenosine monophosphate protein kinase, and inhibit microRNA-221 and microRNA-222 for the purpose of reducing microRNA-221 and -222 levels in the vasculature. Reduction of microRNA-221 and -222 in the vasculature of diabetic patients restores normal levels of intimal thickening and enhances the effectiveness of the standard of care in diabetic subjects.